新疆百花村医药集团股份有限公司

Core Viewpoint - The company is undergoing significant governance changes, including the cancellation of the supervisory board and amendments to the articles of association, which require shareholder approval [8][10][22]. Group 1: Governance Changes - The company plans to cancel the supervisory board and amend the articles of association, with non-substantive changes such as renaming "shareholders' meeting" to "shareholders' assembly" and changing "supervisory board" to "audit committee" [1][2][8]. - The amendments to the articles of association and related rules will be submitted for shareholder approval [9][10][22]. Group 2: Board Meeting Details - The company's ninth board meeting was held on August 20, 2025, with all 10 directors present, and the meeting was deemed valid [5]. - The board approved the 2025 semi-annual report and the proposal to cancel the supervisory board, with unanimous votes [6][8]. Group 3: Stock Option Plan - The company has decided to cancel 74,040 stock options from the 2021 stock option incentive plan due to failure to meet exercise conditions, completing the implementation of the plan [29][31]. - Following the cancellation, the total number of stock options exercised was 9,413,280, representing 62.76% of the total granted [32][34].